Prospective study of immunological factors in non-inflammatory bowel disease enterocutaneous fistulas
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
AbstractBackground: Enterocutaneous fistulas (ECF) are debilitating and usually result following complex abdominal surgery. While there is an association with inflammatory bowel disease (IBD), a large number of fistulas occur after surgery not related to IBD. The consequences of ECF include short bowel syndrome and the need for long term parenteral nutrition. ECF can heal spontaneously and in the case of IBD can be cured by medical therapy in some instances. Those that do not resolve spontaneously have to be cured by surgery which is complex and associated with a high morbidity. It is not considered traditional treatment to use the same medical therapy as in IBD to cure ECF caused by other conditions. A small case series has reported three patients with persistent ECF not related to IBD to have healed following use of Infliximab which is the treatment commonly used for ECF caused by IBD. Infliximab acts by inhibiting the activity of the inflammatory cytokine TNF- alpha. It is not known if this cytokine is present in ECF tissue in the absence of IBD. The aim of this study is to demonstrate the presence of inflammatory markers in tissue surrounding non-IBD ECF and in particular to quantify the presence of the cytokine TNF- alpha. We hypothesise that TNF - alpha levels are raised in non-IBD ECF. Methods/Design. Tissue and serum from ECF of IBD and non-IBD patients will be prospectively collected at St. Mark's Hospital Intestinal Failure Unit. The control group will consist of patients undergoing colonoscopy for bowel cancer screening, with normal findings. Biopsies of the terminal ileum will be obtained from this group during colonoscopy. The fistula tract and serum cytokine profiles of interleukins (IL)-1a, IL-1b, IL-2, IL-4, IL-6, IL-8, IL-10, TNF- alpha, IFN-y, MCP-1, EGF and VEGF will be assessed. Discussion. This study aims to assess the presence or absence of TNF- alpha expression in the ECF tissue in non-IBD origin. If our hypothesis is correct we would then be able to study the use of the TNF- alpha inhibitor Infliximab as a therapeutic option in the treatment of non-IBD ECF. Secondary aims include assessing the spectrum of inflammatory cytokines and markers present in tissue and serum of non-IBD ECF when compared with IBD ECF and normal controls. © 2011 Rahbour et al; licensee BioMed Central Ltd.
CitationRahbour, G., Hart, A.L., Al-Hassi, H.O. et al. (2011) Prospective study of immunological factors in non-inflammatory bowel disease enterocutaneous fistulas. BMC Surgery, 11, 12. https://doi.org/10.1186/1471-2482-11-12
PublisherSpringer Science and Business Media LLC
PubMed ID21619579 (pubmed)
Description© 2011 The Authors. Published by BMC, part of Springer Nature. This is an open access article available under a Creative Commons licence. The published version can be accessed at the following link on the publisher’s website: https://doi.org/10.1186/1471-2482-11-12
SponsorsThe study has secured funding from Bowel Disease Research Foundation (BDRF).
Except where otherwise noted, this item's license is described as Licence for published version: Creative Commons Attribution 4.0 International
- Prospective study of immunological factors in non-inflammatory bowel disease enterocutaneous fistulas.
- Authors: Rahbour G, Hart AL, Al-Hassi HO, Ullah MR, Gabe SM, Knight SC, Warusavitarne J, Vaizey CJ
- Issue date: 2011 May 27
- Pilot study of immunological factors in non-inflammatory bowel disease enterocutaneous fistulas.
- Authors: Rahbour G, Warusavitarne J, Hart AL, Tozer PJ, Ullah MR, Thomas GP, Gabe SM, Knight SC, Al-Hassi HO, Vaizey CJ
- Issue date: 2017 May
- Long-term outcome of enterocutaneous fistula in patients with Crohn's disease treated with anti-TNF therapy: a cohort study from the GETAID.
- Authors: Amiot A, Setakhr V, Seksik P, Allez M, Treton X, De Vos M, Laharie D, Colombel JF, Abitbol V, Reimund JM, Moreau J, Veyrac M, Flourié B, Cosnes J, Lemann M, Bouhnik Y
- Issue date: 2014 Sep
- Cytokines in inflammatory bowel disease.
- Authors: Kmieć Z
- Issue date: 1998